200 related articles for article (PubMed ID: 26849373)
1. Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas.
Saito T; Muragaki Y; Maruyama T; Komori T; Tamura M; Nitta M; Tsuzuki S; Kawamata T
Brain Tumor Pathol; 2016 Jul; 33(3):175-82. PubMed ID: 26849373
[TBL] [Abstract][Full Text] [Related]
2. 11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors.
Saito T; Maruyama T; Muragaki Y; Tanaka M; Nitta M; Shinoda J; Aki T; Iseki H; Kurisu K; Okada Y
AJNR Am J Neuroradiol; 2013 Jan; 34(1):85-91. PubMed ID: 22766670
[TBL] [Abstract][Full Text] [Related]
3. Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas.
Stockhammer F; Thomale UW; Plotkin M; Hartmann C; Von Deimling A
J Neurosurg; 2007 Apr; 106(4):633-7. PubMed ID: 17432715
[TBL] [Abstract][Full Text] [Related]
4. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
5. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas.
Jansen NL; Schwartz C; Graute V; Eigenbrod S; Lutz J; Egensperger R; Pöpperl G; Kretzschmar HA; Cumming P; Bartenstein P; Tonn JC; Kreth FW; la Fougère C; Thon N
Neuro Oncol; 2012 Dec; 14(12):1473-80. PubMed ID: 23090986
[TBL] [Abstract][Full Text] [Related]
6. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors.
Scheie D; Andresen PA; Cvancarova M; Bø AS; Helseth E; Skullerud K; Beiske K
Am J Surg Pathol; 2006 Jul; 30(7):828-37. PubMed ID: 16819324
[TBL] [Abstract][Full Text] [Related]
8. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
[TBL] [Abstract][Full Text] [Related]
10. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
Huang L; Jiang T; Yuan F; Li GL; Cui Y; Liu EZ; Wang ZC
Neuropathol Appl Neurobiol; 2009 Aug; 35(4):367-379. PubMed ID: 19019173
[TBL] [Abstract][Full Text] [Related]
11. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y
Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974
[TBL] [Abstract][Full Text] [Related]
12. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas.
Thon N; Eigenbrod S; Grasbon-Frodl EM; Ruiter M; Mehrkens JH; Kreth S; Tonn JC; Kretzschmar HA; Kreth FW
J Neuropathol Exp Neurol; 2009 Nov; 68(11):1219-28. PubMed ID: 19816195
[TBL] [Abstract][Full Text] [Related]
13. Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases.
Scheie D; Meling TR; Cvancarova M; Skullerud K; Mørk S; Lote K; Eide TJ; Helseth E; Beiske K
Neuro Oncol; 2011 Nov; 13(11):1225-33. PubMed ID: 21856683
[TBL] [Abstract][Full Text] [Related]
14. [Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour].
Born PW; Broholm H; Laursen H
Ugeskr Laeger; 2006 Oct; 168(44):3813-6. PubMed ID: 17118240
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Kaloshi G; Benouaich-Amiel A; Diakite F; Taillibert S; Lejeune J; Laigle-Donadey F; Renard MA; Iraqi W; Idbaih A; Paris S; Capelle L; Duffau H; Cornu P; Simon JM; Mokhtari K; Polivka M; Omuro A; Carpentier A; Sanson M; Delattre JY; Hoang-Xuan K
Neurology; 2007 May; 68(21):1831-6. PubMed ID: 17515545
[TBL] [Abstract][Full Text] [Related]
16. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?
Ramirez C; Bowman C; Maurage CA; Dubois F; Blond S; Porchet N; Escande F
Neuro Oncol; 2010 May; 12(5):490-9. PubMed ID: 20156805
[TBL] [Abstract][Full Text] [Related]
17. MRI and CT Identify Isocitrate Dehydrogenase
Patel SH; Batchala PP; Mrachek EKS; Lopes MS; Schiff D; Fadul CE; Patrie JT; Jain R; Druzgal TJ; Williams ES
Radiology; 2020 Jan; 294(1):160-167. PubMed ID: 31714193
[TBL] [Abstract][Full Text] [Related]
18. The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making.
Kanner AA; Staugaitis SM; Castilla EA; Chernova O; Prayson RA; Vogelbaum MA; Stevens G; Peereboom D; Suh J; Lee SY; Tubbs RR; Barnett GH
J Neurosurg; 2006 Apr; 104(4):542-50. PubMed ID: 16619658
[TBL] [Abstract][Full Text] [Related]
19. Objective response to radiation therapy and long-term survival of patients with WHO grade II astrocytic gliomas with known LOH 1p/19q status.
Fathi AR; Vassella E; Arnold M; Curschmann J; Reinert M; Vajtai I; Weis J; Deiana G; Mariani L
Strahlenther Onkol; 2007 Sep; 183(9):517-22. PubMed ID: 17762927
[TBL] [Abstract][Full Text] [Related]
20. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
Watanabe T; Nakamura M; Kros JM; Burkhard C; Yonekawa Y; Kleihues P; Ohgaki H
Acta Neuropathol; 2002 Mar; 103(3):267-75. PubMed ID: 11907807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]